Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Rewards and advancements for clinical pharmacists.

Goodwin SD, Kane-Gill SL, Ng TM, Melroy JT, Hess MM, Tallian K, Trujillo TC, Vermeulen LC.

Pharmacotherapy. 2010 Jan;30(1):114. doi: 10.1592/phco.30.1.114.

PMID:
20030483
2.

Impact of an educational program on efficacy and adherence with a twice-daily lamivudine/zidovudine/abacavir regimen in underrepresented HIV-infected patients.

Rawlings MK, Thompson MA, Farthing CF, Brown LS, Racine J, Scott RC, Crawford KH, Goodwin SD, Tolson JM, Williams VC, Shaefer MS; NZTA4006 Helping to Enhance Adherence to Antiretroviral Therapy (HEART) Study Team.

J Acquir Immune Defic Syndr. 2003 Oct 1;34(2):174-83.

PMID:
14526206
3.

Lamivudine 300 mg QD versus continued lamivudine 150 mg BID with stavudine and a protease inhibitor in suppressed patients.

Sension MG, Bellos NC, Johnson J, Sepulveda GE, DeJesus E, Santana JL, Ames MH, Goodwin SD.

HIV Clin Trials. 2002 Sep-Oct;3(5):361-70.

PMID:
12407485
4.

Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients.

Skowron G, Kuritzkes DR, Thompson MA, Squires KE, Goodwin SD, Dusak BA, Tolson JM, Stevens M, Yuen GJ, Rooney JF; Intercompany Collaboration for AIDS Drug Development Protocol 604 Team.

J Infect Dis. 2002 Oct 1;186(7):1028-33. Epub 2002 Sep 13. Erratum in: J Infect Dis 2002 Dec 15;186(12):1872.

PMID:
12232846
5.

Stability of sumatriptan succinate in extemporaneously prepared oral liquids.

Fish DN, Beall HD, Goodwin SD, Fox JL.

Am J Health Syst Pharm. 1997 Jul 15;54(14):1619-22.

PMID:
9248606
6.

Rapid postmortem invasion of cecal mucosa of macaques by nonpathogenic Entamoeba chattoni.

Vogel P, Zaucha G, Goodwin SD, Kuehl K, Fritz D.

Am J Trop Med Hyg. 1996 Dec;55(6):595-602.

PMID:
9025684
7.

Criteria for use of atovaquone oral suspension in adult inpatients and outpatients.

Goodwin SD, Fish DN.

Am J Health Syst Pharm. 1995 Nov 1;52(21):2460-2. No abstract available.

PMID:
8564614
8.

Pretreatment regimens for adverse events related to infusion of amphotericin B.

Goodwin SD, Cleary JD, Walawander CA, Taylor JW, Grasela TH Jr.

Clin Infect Dis. 1995 Apr;20(4):755-61.

PMID:
7795069
9.

Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection.

Goodwin SD, Gallis HA, Chow AT, Wong FA, Flor SC, Bartlett JA.

Antimicrob Agents Chemother. 1994 Apr;38(4):799-804.

10.

Use of antifungal therapy in hospitalized patients. II. Results after the marketing of fluconazole.

Grasela TH, Pasko MT, Goodwin SD, Walawander CA, Blackwelder N, Bruder-Holt RJ.

Ann Pharmacother. 1994 Feb;28(2):261-70.

PMID:
8173148
11.

Use of antifungal therapy in hospitalized patients. I. Results prior to the marketing of fluconazole.

Grasela TH, Goodwin SD, Pasko MT, Walawander CA, Raebel MA.

Ann Pharmacother. 1994 Feb;28(2):252-60.

PMID:
8173147
12.

Pneumocystis carinii pneumonia in human immunodeficiency virus-infected infants and children.

Goodwin SD.

Pharmacotherapy. 1993 Nov-Dec;13(6):640-6. Review.

PMID:
8302691
13.

Antifungal prophylaxis in immunocompromised hosts.

Reents S, Goodwin SD, Singh V.

Ann Pharmacother. 1993 Jan;27(1):53-60. Review.

PMID:
8431623
15.

Introduction to the "HIV and AIDS" column.

Goodwin SD, Fletcher CV.

Ann Pharmacother. 1992 May;26(5):700. No abstract available.

PMID:
1591434
16.

Pharmaceutical care for patients with HIV infection.

Goodwin SD.

Ann Pharmacother. 1992 May;26(5):698-9. No abstract available.

PMID:
1591433
17.

Criteria for use of zidovudine in adult and pediatric inpatients and outpatients.

Goodwin SD, Shipp KW.

Clin Pharm. 1992 Jan;11(1):63-8. No abstract available.

PMID:
1730181
18.

A nationwide survey of clinical laboratory methodologies for fungal infections.

Goodwin SD, Fiedler-Kelly J, Grasela TH, Schell WA, Perfect JR.

J Med Vet Mycol. 1992;30(2):153-60.

PMID:
1588465
19.

Compatibility of ciprofloxacin injection with selected drugs and solutions.

Goodwin SD, Nix DE, Heyd A, Wilton JH.

Am J Hosp Pharm. 1991 Oct;48(10):2166-71.

PMID:
1781473
20.

Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response.

Nix DE, Goodwin SD, Peloquin CA, Rotella DL, Schentag JJ.

Antimicrob Agents Chemother. 1991 Oct;35(10):1953-9. Review. No abstract available.

21.

Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning.

Nix DE, Goodwin SD, Peloquin CA, Rotella DL, Schentag JJ.

Antimicrob Agents Chemother. 1991 Oct;35(10):1947-52. Review. No abstract available.

22.

Criteria for use of fluconazole in adult and pediatric inpatients and outpatients.

Bourne KM, Goodwin SD.

Clin Pharm. 1991 Mar;10(3):222-7. Review. No abstract available.

PMID:
2040130
23.

Management of Lyme disease.

Goodwin SD, Sproat TT, Russell WL.

Clin Pharm. 1990 Mar;9(3):192-205. Review.

PMID:
2180624
24.

Trimethoprim-sulfamethoxazole anaphylactoid reactions in patients with AIDS: case reports and literature review.

Johnson MP, Goodwin SD, Shands JW Jr.

Pharmacotherapy. 1990;10(6):413-6. Review.

PMID:
2287564
25.

Prospective surveillance of intravenous amphotericin B use patterns.

Grasela TH Jr, Goodwin SD, Walawander MK, Cramer RL, Fuhs DW, Moriarty VP.

Pharmacotherapy. 1990;10(5):341-8. Review.

PMID:
2235670
26.

Comparison of the safety and efficacy of intravenous ciprofloxacin and intravenous ceftazidime in the treatment of selected infections.

Gallis HA, Brennan RO, Goodwin SD, Swinney V, Rumbaugh MM, Drew RH.

Am J Med. 1989 Nov 30;87(5A):176S-180S.

PMID:
2686418
27.

Eligibility of inpatients for antibiotic trials.

Goodwin SD, Hudson WP, Gallis HA.

Drug Intell Clin Pharm. 1988 Nov;22(11):918-9. No abstract available.

PMID:
3069431
28.

Hardiness and psychosocial adjustment in hemodialysis clients.

Goodwin SD.

ANNA J. 1988 Aug;15(4):211-6. No abstract available.

PMID:
3421742
29.

Single-dose pharmacokinetics of cefuroxime and cefamandole in healthy subjects.

Colaizzi PA, Goodwin SD, Poynor WJ, Karnes HT, Polk RE.

Clin Pharm. 1987 Nov;6(11):894-9. No abstract available.

PMID:
3677567
30.

Biochemical and behavioral effects of intrahippocampal AF64A in rats.

Blaker WD, Goodwin SD.

Pharmacol Biochem Behav. 1987 Oct;28(2):157-63.

PMID:
3685051
31.

Temporary use of an eroded bipolar pacemaker system.

Tyndal EC, Goodwin SD.

Am Surg. 1984 Aug;50(8):446-9.

PMID:
6465692
32.

Purification of cell wall peptidoglycan of the dimorphic bacterium Caulobacter crescentus.

Goodwin SD, Shedlarski JG Jr.

Arch Biochem Biophys. 1975 Sep;170(1):23-36. No abstract available.

PMID:
1164030
33.
34.

Peptides from human blood-group-specific glycoproteins.

Goodwin SD, Watkins WM.

Biochem J. 1971 Dec;125(3):79P-80P. No abstract available.

35.

Biosynthesis of blood group active glycoproteins: a peptidyl: alpha-N-acetylgalactosaminyltransferase from human submaxillary gland and stomach mucosal tissue.

Hearn VM, Goodwin SD, Watkins WM.

Biochem Biophys Res Commun. 1970 Dec 9;41(5):1279-86. No abstract available.

PMID:
5483631

Supplemental Content

Loading ...
Support Center